Status:

ACTIVE_NOT_RECRUITING

Development of Adaptive Deep Brain Stimulation for OCD

Lead Sponsor:

Baylor College of Medicine

Collaborating Sponsors:

University of Pittsburgh

Brown University

Conditions:

Obsessive-Compulsive Disorder

Eligibility:

All Genders

21-70 years

Phase:

NA

Brief Summary

This research study is for participants that have been diagnosed with intractable Obsessive -compulsive disorder (OCD). OCD is a persistent and oftentimes disabling disorder marked by unwanted and dis...

Detailed Description

ENROLLMENT: A subject is considered enrolled upon signing informed consent, deemed eligible to be screened by the investigator. The informed consent process may include discussions with the patient¿s ...

Eligibility Criteria

Inclusion

  • OCD DBS Subject Inclusion criteria:
  • Signed informed consent prior to any study specific procedures being performed
  • Male or female between ages 21 and 70;
  • At least a five-year history of treatment-refractory OCD that causes substantial subjective distress and impairment in functioning;
  • Y-BOCS minimum score of 28;
  • Failed an adequate trial of at least three of the following SSRIs:
  • Fluoxetine; fluvoxamine; citalopram; escitalopram; sertraline; paroxetine;
  • Failed an adequate trial of clomipramine;
  • Failed augmentation of one or more of the aforementioned drugs with at least one of the following antipsychotics: haloperidol; risperidone; quetiapine; ziprasidone; aripiprazole;
  • Failed an adequate trial of CBT for OCD, defined as 25 hours of documented exposure and response prevention (ERP) by an expert therapist;
  • Stable psychotropic medical regimen for the month preceding surgery
  • Non-Implanted Control Subject Inclusion criteria:
  • Signed informed consent prior to any study specific procedures being performed
  • Male or female between ages 21 and 70

Exclusion

  • OCD DBS Subject Exclusion criteria:
  • Inability or refusal to give informed consent.
  • Lifetime diagnosis of psychotic disorders such as schizophrenia;
  • Alcohol or substance abuse/dependence within 6 months, excluding nicotine;
  • Deemed at high risk of suicidal behavior or impulsivity, per clinical opinion assessments.
  • Any Neurological/Medical condition that makes the subject, in the opinion of the surgeon, a poor candidate.
  • Pregnant (confirmed by serum pregnancy test on females of child bearing age) or plans to become pregnant in the next 24 months.
  • Need for Diathermy
  • Contraindications to MRI
  • Non-Implanted Control Subject Exclusion criteria:
  • Inability or refusal to give informed consent.
  • Lifetime diagnosis of mental illness
  • A score of 8 or greater on part B of the Florida Obsessive Compulsive Inventory
  • Any neurological disorders (i.e., MS, Parkinson's Disease, seizure disorders, etc.) or evidence of brain abnormalities/injury, such as tumor, stroke, or traumatic brain injury
  • Pregnant (confirmed by self-report for females of child bearing age)
  • Contraindications to MRI

Key Trial Info

Start Date :

October 11 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2026

Estimated Enrollment :

3 Patients enrolled

Trial Details

Trial ID

NCT04281134

Start Date

October 11 2019

End Date

June 1 2026

Last Update

April 17 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

University of Pittsburgh

Pittsburgh, Pennsylvania, United States, 15260

2

Brown University

Providence, Rhode Island, United States, 02912

3

Baylor College of Medicine

Houston, Texas, United States, 77030